MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Why Amazon Rules Retail
- Wave of Debt Payments Facing US Government
- China Eastern to Complete Shanghai Air Buy by End '09
- Paul: Audit the Fed
- Gold Will Collapse Like Oil Did in 2008: Charts
- The Social Media Gaming Threat
- Prepare For Large Decline In Stocks, Next Year?
- JAL Slides to Record Low on Bankruptcy Jitters
- Nielsen Ratings Coming to Video Games
- Weak Dollar Is Golden for Mining Companies
- How Many US Consumers Will Shop this Weekend?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- World's Largest Share Issue Priced at Deep Discount
- GE Capital Losses May See Dramatic Fall: JP Morgan
- Obama says Boosting US Jobs is Top Priority
- Why the Dollar Will Likely Stay Weak for Some Time
- Playboy to Outsource Most Magazine Operations: Report
- General Motors to Cut up to 9,500 Jobs in Europe
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
Text Size 
SEATTLE, Oct 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following upcoming investor conferences.
Merriman Investor Summit 2009 New York City Tuesday, November 10, 2009 11:00 a.m. ET Credit Suisse 2009 Healthcare Conference Phoenix, Arizona Friday, November 13, 2009 11:30 a.m. ET Lazard Capital Markets 6th Annual Healthcare Conference New York City Tuesday, November 17, 2009 10:55 a.m. ET The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
SOURCE Dendreon Corporation URL: http://www.dendreon.com www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0- KEYWORD: Washington INDUSTRY KEYWORD: BIO
HEA SUBJECT CODE: TDS
CCA
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes